Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2019.10856

OL-0-0-10856

Corrigendum

Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway

Jiang

Jian

Chen

Yaodong

Dong

Tianxiu

Yue

Minlu

Zhang

Tingting

Zhang

Jiuwei

Liu

Pengfei

Yang

Xiuhua

11 2019

12 09 2019

18 5 5654 5654

2019

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Oncol Lett 17: 4505-4513, 2019; DOI: 10.3892/ol.2019.10123

Subsequently to the publication of this article, the authors have realized that Fig. 3 contained a duplicated panel: In Fig. 3A, the data correctly shown for the 0 h, ‘Control’ panel was inadvertently copied across to the 0 h, ‘100 µmol/l’ panel. The revised version of Fig. 3, featuring the correct data for the 0 h, ‘100 µmol/l’ panel, is shown opposite.

Note that this error did not affect the overall conclusions reported in the paper. The authors apologize to the Editor of Oncology Letters and to readership for any inconvenience caused.

Figure 3.

Polydatin inhibits migration of HCCLM3 cells. (A) Suppressive effects of polydatin on migration were assessed via wound healing assay (magnification, ×200). (B) Statistical analysis of the relative distances of cell migration. (C) Migration assay of HCCLM3 cells following treatment with polydatin at non-cytotoxic concentrations (0–150 μmol/l) (magnification, ×200). (D) Statistical analysis of the number of cells crossing the membrane. ^***P<0.001 vs. control.